Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 2124143, Jackson, Wisconsin, United States. Part of Wisconsin Pharmacal Company's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations and its recalls since 2016.
Inspections: 7
Official action indicated: 1
Last inspection ended: Mar 7, 2025
Warning letters: 1
Recalls since 2016: 1
Inspections by Fiscal Year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
21 CFR 211.100(a). Absence of Written Procedures There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
21 CFR 820.100(a). Lack of or inadequate procedures Procedures for corrective and preventive action have not been adequately established.
21 CFR 211.22(b). Adequate lab facilities not available Adequate lab facilities for testing and approval or rejection of components and drug products are not available to the quality control unit.
21 CFR 820.90(a). Nonconforming product, Lack of or inadequate procedures Procedures have not been adequately established to control product that does not conform to specified requirements.
21 CFR 211.25(a). Training , Education , Experience overall Employees engaged in the manufacture, processing, packing, and holding of a drug product lack the training required to perform their assigned functions.
21 CFR 211.160(a). Following/documenting laboratory controls Established test procedures are not documented at the time of performance.
21 CFR 820.22. Quality Audits - defined intervals Quality audits were not performed at defined intervals and at sufficient frequency to determine whether the quality system activities and results comply with quality system procedures.
21 CFR 820.75(a). Documentation Process validation activities and results have not been adequately documented and adequately approved.
21 CFR 211.67(b). Written procedures fail to include Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used.
21 CFR 820.30(j). Design history file The design history file does not demonstrate that the design was developed following the approved design plan and does not demonstrate that the design was developed following the requirements of 21 CFR 820.
21 CFR 211.165(e). Test methods The accuracy, sensitivity, specificity, and reproducibility of test methods have not been established and documented.
21 CFR 211.198(a). Complaint Handling Procedure Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
21 CFR 820.198(c). Investigation of device failures Complaints involving the possible failure of a device to meet any of its specifications were not evaluated and investigated where necessary.
21 CFR 211.166(a)(3). Valid stability test methods The written stability program for drug products does not include reliable test methods.
Voluntary Action Indicated (VAI)
Jul 11, 2012
Devices · Compliance: DevicesDrugs · Drug Quality Assurance
14 cited references
21 CFR 211.67(b). Written procedures fail to include Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used.
21 CFR 211.22(b). Adequate lab facilities not available Adequate lab facilities for testing and approval or rejection of components and drug products are not available to the quality control unit.
21 CFR 211.166(a)(3). Valid stability test methods The written stability program for drug products does not include reliable test methods.
21 CFR 820.100(b). Documentation Corrective and preventive action activities and/or results have not been adequately documented.
21 CFR 211.165(e). Test methods The accuracy, sensitivity, specificity, and reproducibility of test methods have not been established and documented.
21 CFR 211.100(a). Absence of Written Procedures There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
21 CFR 820.50. Purchasing controls, Lack of or inadequate procedures Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
21 CFR 211.198(b)(2). Complaint Investigation/Follow-Up Findings Complaint records are deficient in that they do not include the findings of the investigation and follow-up.
21 CFR 211.113(a). Procedures for non-sterile drug products Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established.
21 CFR 211.84(d)(2). Reports of Analysis (Components) Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.
21 CFR 211.67(a). Cleaning / Sanitizing / Maintenance Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
21 CFR 820.30(a). Design control - no procedures Procedures for design control have not been established.
21 CFR 211.25(c). Inadequate number of personnel The number of qualified personnel is inadequate to perform and supervise the manufacture, processing, packing, and holding of each drug product.
21 CFR 820.70(a). Production processes Production processes were not developed to ensure that a device conforms to its specifications.
Voluntary Action Indicated (VAI)
Oct 12, 2011
Drugs · Drug Quality AssuranceDevices · Compliance: Devices
10 cited references
21 CFR 820.90(a). Nonconforming product, Lack of or inadequate procedures Procedures have not been adequately established to control product that does not conform to specified requirements.
21 CFR 820.198(c). Investigation of device failures Complaints involving the possible failure of a device to meet any of its specifications were not investigated where necessary.
21 CFR 820.70(a). Production processes Production processes were not developed to ensure that a device conforms to its specifications.
21 CFR 820.30(a). Design control - no procedures Procedures for design control have not been established.
21 CFR 820.30(h). Design transfer - Lack of or inadequate procedures Procedures for design transfer have not been established.
21 CFR 820.25(b). Training - Lack of or inadequate procedures Procedures for training and identifying training needs have not been adequately established.
21 CFR 820.22. Quality Audit/Reaudit - conducted Quality audits have not been performed.
21 CFR 820.50(a)(3). Acceptable supplier records, inadequate records Records of acceptable suppliers, contractors, and consultants have not been established.
21 CFR 820.40. Procedures not adequately established or maintained Document control procedures have not been adequately established.
21 CFR 820.100(a). Lack of or inadequate procedures Procedures for corrective and preventive action have not been adequately established.
No Action Indicated (NAI)
Jun 14, 2011
Drugs · Drug Quality AssuranceDevices · Compliance: Devices
11 cited references
21 CFR 211.166(a)(3). Valid stability test methods The written stability program for drug products does not include reliable test methods.
21 CFR 820.50(a). Evaluation of suppliers, contractors, etc., requirements Requirements that must be met by suppliers have not been adequately established.
21 CFR 211.84(d)(2). Reports of Analysis (Components) Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.
21 CFR 211.67(a). Cleaning / Sanitizing / Maintenance Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
21 CFR 820.70(a). Production processes Production processes were not developed, conducted, and monitored to ensure that a device conforms to its specifications.
21 CFR 111.113(b)(2). Quality control - reject; specification not met Your quality control personnel did not reject a dietary supplement when an established specification was not met.
21 CFR 211.166(b). Adequate number of batches on stability An adequate number of batches of each drug product are not tested to determine an appropriate expiration date.
21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
21 CFR 211.100(a). Absence of Written Procedures There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
21 CFR 211.192. Written record of investigation incomplete Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
21 CFR 211.165(e). Test methods The accuracy, sensitivity, specificity, and reproducibility of test methods have not been established and documented.
Voluntary Action Indicated (VAI)
Warning Letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm.FDA Data Dashboard, warning letters and enforcement reports